Literature DB >> 24900269

Highly Selective and Potent Thiophenes as PI3K Inhibitors with Oral Antitumor Activity.

Kevin K-C Liu1, JinJiang Zhu1, Graham L Smith1, Min-Jean Yin1, Simon Bailey1, Jeffrey H Chen1, Qiyue Hu1, Qinhua Huang1, Chunze Li1, Qing J Li1, Matthew A Marx1, Genevieve Paderes1, Paul F Richardson1, Neal W Sach1, Marlena Walls1, Peter A Wells1, Sangita Baxi, Aihua Zou1.   

Abstract

Highly selective PI3K inhibitors with subnanomolar PI3Kα potency and greater than 7000-fold selectivity against mTOR kinase were discovered through structure-based drug design (SBDD). These tetra-substituted thiophenes were also demonstrated to have good in vitro cellular potency and good in vivo oral antitumor activity in a mouse PI3K driven NCI-H1975 xenograft tumor model. Compounds with the desired human PK predictions and good in vitro ADMET properties were also identified. In this communication, we describe the rationale behind the installation of a critical triazole moiety to maintain the intricate H-bonding network within the PI3K receptor leading to both better potency and selectivity. Furthermore, optimization of the C-4 phenyl group was exploited to maximize the compounds mTOR selectivity.

Entities:  

Keywords:  Kinase inhibitor; PI3K; antitumor activity; mTOR; thiophene; triazole

Year:  2011        PMID: 24900269      PMCID: PMC4018126          DOI: 10.1021/ml200126j

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  6 in total

1.  High frequency of mutations of the PIK3CA gene in human cancers.

Authors:  Yardena Samuels; Zhenghe Wang; Alberto Bardelli; Natalie Silliman; Janine Ptak; Steve Szabo; Hai Yan; Adi Gazdar; Steven M Powell; Gregory J Riggins; James K V Willson; Sanford Markowitz; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu
Journal:  Science       Date:  2004-03-11       Impact factor: 47.728

Review 2.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism.

Authors:  Jeffrey A Engelman; Ji Luo; Lewis C Cantley
Journal:  Nat Rev Genet       Date:  2006-08       Impact factor: 53.242

3.  4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors.

Authors:  Kevin K-C Liu; Shubha Bagrodia; Simon Bailey; Hengmiao Cheng; Hui Chen; Lisa Gao; Samantha Greasley; Jacqui E Hoffman; Qiyue Hu; Ted O Johnson; Dan Knighton; Zhengyu Liu; Matthew A Marx; Mitchell D Nambu; Sacha Ninkovic; Bernadette Pascual; Kristina Rafidi; Caroline M-L Rodgers; Graham L Smith; Shaoxian Sun; Haitao Wang; Anle Yang; Jing Yuan; Aihua Zou
Journal:  Bioorg Med Chem Lett       Date:  2010-08-14       Impact factor: 2.823

4.  Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors.

Authors:  Kevin K C Liu; Xiaojun Huang; Shubha Bagrodia; Jeffrey H Chen; Samantha Greasley; Hengmiao Cheng; Shaoxian Sun; Dan Knighton; Caroline Rodgers; Kristina Rafidi; Aihua Zou; Jiezhan Xiao; Shengyong Yan
Journal:  Bioorg Med Chem Lett       Date:  2010-12-10       Impact factor: 2.823

Review 5.  Growing roles for the mTOR pathway.

Authors:  Dos D Sarbassov; Siraj M Ali; David M Sabatini
Journal:  Curr Opin Cell Biol       Date:  2005-10-13       Impact factor: 8.382

Review 6.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations.

Authors:  Jeffrey A Engelman
Journal:  Nat Rev Cancer       Date:  2009-08       Impact factor: 60.716

  6 in total
  3 in total

1.  Discovery of a Novel Series of Thienopyrimidine as Highly Potent and Selective PI3K Inhibitors.

Authors:  Fangbin Han; Songwen Lin; Peng Liu; Xiujie Liu; Jing Tao; Xiaobing Deng; Chongqin Yi; Heng Xu
Journal:  ACS Med Chem Lett       Date:  2015-03-11       Impact factor: 4.345

Review 2.  Recent syntheses of PI3K/Akt/mTOR signaling pathway inhibitors.

Authors:  Mark E Welker; George Kulik
Journal:  Bioorg Med Chem       Date:  2013-05-09       Impact factor: 3.641

Review 3.  Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents.

Authors:  Yu Liu; Wen-Zhu Wan; Yan Li; Guan-Lian Zhou; Xin-Guang Liu
Journal:  Oncotarget       Date:  2017-01-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.